随着工程化免疫疗法的发展和对抗体药物研发需求的增加，用于体内研究的细胞因子和抗体的地位也变得越来越重要。
细胞因子由巨噬细胞、B淋巴细胞、T淋巴细胞、自然杀伤细胞和成纤维细胞产生。由于细胞因子在免疫反应中的核心作用，它们成为各种免疫疾病的临床前和临床研究目标。然而，细胞因子在血液中的半衰期短、多效性和脱靶效应等因素，制约了细胞因子的疗效。如何才能为体内研究开发出长效Fc融合蛋白呢？AdipoGen自主研发的InVivoKines™给出了这个问题的答案。Ridgway等人于1996年提出一种名为“Fc-Knobs-into-Holes（简称Fc-KIH）”的方法，这种突破性技术传统上用于开发双特异性抗体，它能使两种不同的Fc片段异源二聚化，从而形成具有两种不同 “臂 ”的结构。AdipoGen应用Fc-KIH技术，提供的InVivoKines™新一代融合蛋白，具有更高的活性和稳定性，用于免疫治疗、临床前和体内转化研究。
InVivoKines™体内研究细胞因子优势 | |
• 具有天然构象——由HEK 293或CHO细胞表达产生 • 无动物源成分条件下生产 • 通过ELISA和基于细胞的分析测试具有高生物活性 • 通过SEC验证纯度＞95% • 低内毒素水平 • 批次间一致性高 |
|
InVivoKinesTM 重组蛋白产品列表
产品名称 | 货号 | 蛋白结构 | Fc-KIH Silenced |
NEW Fc (LALA-PG)-KIH (human):IL-1Ra (mouse) (monomeric) (rec.) | AG-40B-0254 | Monomer | LALA-PG |
IL-2 Superkine (monomeric):Fc-KIH (human) (rec.) | AG-40B-0222 | Monomer | No |
IL-2 Superkine H9T (monomeric):Fc-KIH (human) (rec.) | AG-40B-0223 | Monomer | No |
IL-2 (human) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0224 | Monomer | No |
IL-2 (mouse) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0225 | Monomer | No |
IL-2 (human) (Switch-2) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0234 | Monomer | No |
IL-7 (human) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0238 | Monomer | No |
IL-7 (human) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0247 | Monomer | LALA-PG |
NEW IL-7 (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0256 | Monomer | LALA-PG |
IL-12 (mouse):Fc-KIH (human) (rec.) | AG-40B-0240 | Heterodimer | No |
NEW IL-12 (mouse):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0255 | Heterodimer | LALA-PG |
NEW IL-15 (mouse):IL-15Ra (Sushi) (mouse):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0257 | Heterodimer | LALA-PG |
NEW IL-21 (human) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0258 | Monomer | LALA-PG |
IL-21 (mouse) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0250 | Monomer | LALA-PG |
IL-23 (mouse):Fc-KIH (human) (rec.) | AG-40B-0235 | Heterodimer | No |
IL-23 (mouse):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0248 | Heterodimer | LALA-PG |
IL-27 (mouse):Fc-KIH (human) (rec.) | AG-40B-0236 | Heterodimer | No |
IL-27 (mouse):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0249 | Heterodimer | LALA-PG |
IL-33 (oxidation resistant) (human) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0233 | Monomer | No |
NEW IL-35 (human):Fc (LALA-PG)-KIH (human) (rec.) | AG-40B-0252 | Heterodimer | LALA-PG |
IL-37 (human) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0221 | Monomer | No |
IL-38 (aa 1-152) (human) (monomeric):Fc-KIH (human) (rec.) | AG-40B-0241 | Monomer | No |
BioXcell 重组融合蛋白
BioXcell的Fusion Proteins（融合蛋白）专门为体内研究使用。其纯度＞95%，内毒素水平极低，且不含防腐剂、稳定剂和载体蛋白。
InVivoKinesTM 重组蛋白产品列表
名称 | 货号 | 规格 |
InVivoMAb recombinant human IgG1 Fc | BE0096 | 1mg/5mg/25mg/50mg/100mg |
InVivoMAb recombinant Flt-3L-Ig (hum/hum) | BE0098 | 1mg/5mg/25mg/50mg/100mg |
InVivoMAb recombinant CTLA-4-Ig (hum/hum) | BE0099 | 1mg/5mg/25mg/50mg/100mg |
InVivoPlus recombinant CTLA-4-Ig (hum/hum) | BP0099 | 5mg/25mg/50mg/100mg |
InVivoMAb recombinant Flt-3L-Ig (hum/hum) | BE0342 | 1mg/5mg/25mg/50mg/100mg |
InVivoMAb recombinant mouse IgG2a Fc | BE0097 | 1mg/5mg/25mg/50mg/100mg |
除了融合蛋白，BioXcell还是一家专门提供体内研究用单克隆抗体的公司，具有高纯度、低内毒素、无防腐剂的特点。主要包含以下几类产品：
InVivoMAbTM抗体：用于体内和体外实验，具有高纯度和低内毒素水平，非常适合于体内研究。 | |
InVivoPlusTM抗体：与InVivoMAbTM 相比，内毒素含量更低。 | |
RecombiMabTM重组抗体：旨在减少小鼠模型或人源化小鼠模型中的免疫原性。 | |
InVivoSIMTM抗体：研究级别生物仿制药抗体 | |
同行对照：作为阴性对照抗体 | |
InVivoPureTM稀释缓冲液：一种专门配制的无毒稀释缓冲液，适用于动物模型。 |
BioXcell 体内研究抗体优势
● 超过25年单克隆抗体和重组蛋白生产及定制经验
● 大规模的组织培养生产抗体，亲和层析法纯化抗体
● 性价比高，可提供100mg甚至50g的大包装
● 500多种超纯、低内毒素、无防腐剂的独-特抗体，适用于体内临床前研究
● 20,000多条引用文献
部分热销抗体
靶标 | 应用 | InVivoMab 目录号 | InVivoPlus 目录号 |
PD-1 (CD279) | in vivo blocking of PD-1/PD-L signaling, WB | BE0146 | BP0146 |
in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, WB | BE0033-2 | BP0033-2 | |
PD-L1 (B7-H1) | in vivo and in vitro PD-L1 blockade, IF, IHC-Fr, FC, WB | BE0101 | BP0101 |
CTLA-4 (CD152) | in vivo CTLA-4 neutralization, WB, in vivo intra-tumoral regulatory T cell depletion | BE0164 | BP0164 |
in vivo and in vitro CTLA-4 neutralization, WB | BE0131 | BP0131 | |
CD4 | in vivo CD4+ T cell depletion, FC, WB | BE0003-1 | BP0003-1 |
Ly6G | in vivo neutrophil depletion, in vivo MDSC depletion, IF, IHC, FC | BE0075-1 | BP0075-1 |
in vivo depletion of Gr-1+ myeloid cells, FC, IHC | BE0075 | BP0075 | |
CD8α | in vivo CD8+T cell depletion, WB | BE0061 BE0117 | BP0061 BP0117 |
in vivo CD8+ T cell depletion, IF, FC, WB | BE0004-1 | BP0004-1 | |
OX40 (CD134) | in vivo and in vitro OX40 activation, WB | BE0031 | BP0031 |
CSF1R (CD115) | in vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, FC, WB | BE0213 | BP0213 |
CD40 | in vivoCD40 activation, in vitro B cell stimulation/activation | BE0016-2 | BP0016-2 |
IFNγ | in vivo and in vitro IFNγ neutralization, ELISPOT, FC, WB | BE0055 | BP0055 |
GITR | in vivo GITR stimulation | BE0063 | BP0063 |
CD154 (CD40L) | in vivo and in vitro blocking of CD40/CD40L signaling, WB | BE0017-1 | BP0017-1 |
NK1.1 | in vivo NK cell depletion, FC | BE0036 | BP0036 |
TGF-β | in vivo and in vitro TGFβ neutralization, WB | BE0057 | BP0057 |
部分畅销同型对照抗体
同型对照 | InVivoMab 目录号 | InVivoPlus 目录号 |
Rat IgG2a Isotype control, FC | BE0089 | BP0089 |
Rat IgG2b Isotype control | BE0090 | BP0090 |
Mouse IgG1 Isotype control | BE0083 | BP0083 |
Rat IgG1 Isotype control | BE0088 | BP0088 |
Mouse IgG2a Isotype control | BE0085 | BP0085 |
Mouse IgG2b Isotype control | BE0086 | BP0086 |
Polyclonal Armenian Hamster IgG | BE0091 | BP0091 |
在选择体内研究等级的细胞因子和抗体时，还需要考虑实验的具体需求和目标物种等。如果您需要更详细的建议或有具体的实验应用需要咨询，请联系欣博盛生物。
更多详情，请登录欣博盛网站或关注欣博盛微信
